Patents Assigned to KYOWA KIRIN CO., LTD.
  • Patent number: 12280118
    Abstract: An object of the present invention is to provide a novel IL-2 variant which has improved selectivity for IL-2R??? and selectively activates Tregs. The present invention relates to an IL-2 variant, a method for producing the IL-2 variant, a composition and a therapeutic agent for an immune disease, comprising the IL-2 variant, a method for increasing selectivity of IL-2 for IL-2R???, a method for improving an affinity of IL-2 for an IL-2R? subunit, a method of reducing an affinity of IL-2 for at least one of an IL-2R? subunit and an IL-2R? subunit, and a method for selectively activating regulatory T cells.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: April 22, 2025
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Masahiro Ikeda, Shinpei Yamaguchi, Masumi Murakami, Hideyuki Onodera
  • Patent number: 12258413
    Abstract: The present invention relates to a bispecific antibody in which an N-terminal side polypeptide is bound to an IgG portion that binds to TfR, a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment thereof, a vector containing the DNA, a hybridoma and a transformant that produce the bispecific antibody or the bispecific antibody fragment thereof, a method for producing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic agents containing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic methods using the bispecific antibody or the bispecific antibody fragment thereof, and a reagent for detection or measurement containing the bispecific antibody or the bispecific antibody fragment thereof.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: March 25, 2025
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Keisuke Mitamura, Ryosuke Nakano, Masayuki Kai, Nobuaki Takahashi
  • Publication number: 20250092148
    Abstract: An object of the present invention is to provide a bispecific antibody having an agonist activity to a GM-CSF receptor, and a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody or a bispecific antibody fragment thereof containing: a first antigen-binding domain; and a second antigen-binding domain, in which one of the first antigen-binding domain and the second antigen-binding domain is an antigen-binding domain binding to CD116, and the other one is an antigen-binding domain binding to CD131.
    Type: Application
    Filed: November 29, 2024
    Publication date: March 20, 2025
    Applicant: KYOWA KIRIN CO., LTD.
    Inventors: Akifumi KATO, Harue NISHIYA, Ryosuke NAKANO, Toshimasa HARUMOTO
  • Patent number: 12251446
    Abstract: The present invention provides a nucleic acid conjugate in which a sugar chain ligand is bonded to an oligonucleotide via a linker, the sugar chain ligand having O-bonded mannose at its non-reducing end.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: March 18, 2025
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Keiji Uehara, Yasuhiro Suzuki, Toshimasa Harumoto, Hiroto Iwai, Asana Makino
  • Patent number: 12234292
    Abstract: An antibody or antigen binding fragment thereof that binds to a Fn14, wherein the antibody or antigen binding fragment thereof is an antagonist and non-agonist of Fn14.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: February 25, 2025
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Aihua Song, Andrew John McKnight, Rachel Soloff Nugent, John Lorca Laudenslager, Giuseppe Destito, Sarah Sunrise Bubeck, Shinya Ogawa, Yuji Yamazaki, David Mills, Aruna Bitra, Dirk Michael Zajonc
  • Patent number: 12187803
    Abstract: An object of the present invention is to provide a bispecific antibody having an agonist activity to a GM-CSF receptor, and a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody or a bispecific antibody fragment thereof containing: a first antigen-binding domain; and a second antigen-binding domain, in which one of the first antigen-binding domain and the second antigen-binding domain is an antigen-binding domain binding to CD116, and the other one is an antigen-binding domain binding to CD131.
    Type: Grant
    Filed: February 26, 2024
    Date of Patent: January 7, 2025
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Akifumi Kato, Harue Nishiya, Ryosuke Nakano, Toshimasa Harumoto
  • Publication number: 20240360149
    Abstract: A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).
    Type: Application
    Filed: June 21, 2024
    Publication date: October 31, 2024
    Applicant: KYOWA KIRIN CO., LTD.
    Inventors: Kenji UCHIDA, Ryohei KAWAI, Keisuke YAMAMOTO, Toshimi KANAI, Hideo IKOTA, Takashi IMAEDA, Kei YOSHIDA
  • Publication number: 20240325426
    Abstract: The present invention relates to a polynucleotide, containing a translated region from a start codon to a stop codon, a 5? untranslated region, and a poly A chain, in which 65% or more of nucleotides contained in the poly A chain are sugar-modified nucleotides.
    Type: Application
    Filed: June 30, 2022
    Publication date: October 3, 2024
    Applicants: KYOWA KIRIN CO., LTD., National University Corporation Tokai National Higher Education and Research System
    Inventors: Hiroto Iwai, Masakazu HOMMA, Takayuki ATAGO, Junichiro YAMAMOTO, Hiroshi ABE, Yasuaki KIMURA
  • Publication number: 20240262903
    Abstract: An object of the present invention is to provide an anti-BMP10 antibody, and a therapeutic agent for hypertension and a hypertensive disease, containing the antibody as an active ingredient. The present invention relates to an anti-BMP10 monoclonal antibody or an antibody fragment thereof that binds to human BMP10 (bone morphogenetic protein 10). Further, the present invention relates to a therapeutic agent for hypertension and a hypertensive disease containing an antagonist for at least one of BMP10 and a BMP9/BMP10 heterodimer, a diagnostic agent or a pharmaceutical composition for a disease associated with human BMP10, an immunological detection method or a measurement method for human BMP10 using the antagonist, and use of the antagonist for producing a pharmaceutical composition for treating hypertension and a hypertensive disease.
    Type: Application
    Filed: March 28, 2024
    Publication date: August 8, 2024
    Applicant: Kyowa Kirin Co., Ltd.
    Inventors: Hiroyuki Ariyama, Shinya OGAWA, Tetsuya KITAYAMA, Takenao YAMADA
  • Patent number: 12054494
    Abstract: A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: August 6, 2024
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Kenji Uchida, Ryohei Kawai, Keisuke Yamamoto, Toshimi Kanai, Hideo Ikota, Takashi Imaeda, Kei Yoshida
  • Publication number: 20240207246
    Abstract: The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.
    Type: Application
    Filed: March 7, 2024
    Publication date: June 27, 2024
    Applicant: Kyowa Kirin Co., Ltd.
    Inventors: Hiroki HANIUDA, Sachiko ENOKIZONO, Tomoyuki NAKAZATO, Takuya TOKUDA, Norie FUJIKI
  • Publication number: 20240191179
    Abstract: An object of the present invention is to provide a culture method by which an LMWS amount is minimized while high productivity of a target protein is maintained. The present invention relates to a method for preventing generation of a degradation product (a low molecular weight species: LMWS) of a target protein. The method includes: a means for, in a cell culture process for producing the target protein at a high concentration in a culture medium, removing a reactive oxygen species in the culture medium.
    Type: Application
    Filed: April 22, 2022
    Publication date: June 13, 2024
    Applicant: KYOWA KIRIN CO., LTD.
    Inventors: Tsuyoshi YAMAGUCHI, Mie FUKUDA, Hiroko ISHIKAWA, Ryuma NAGANO, Toshiyuki SUZAWA
  • Publication number: 20240190980
    Abstract: An object of the present invention is to provide a bispecific antibody having an agonist activity to a GM-CSF receptor, and a bispecific antibody fragment thereof. The present invention relates to a bispecific antibody or a bispecific antibody fragment thereof containing: a first antigen-binding domain; and a second antigen-binding domain, in which one of the first antigen-binding domain and the second antigen-binding domain is an antigen-binding domain binding to CD116, and the other one is an antigen-binding domain binding to CD131.
    Type: Application
    Filed: February 26, 2024
    Publication date: June 13, 2024
    Applicant: KYOWA KIRIN CO., LTD.
    Inventors: Akifumi KATO, Harue NISHIYA, Ryosuke NAKANO, Toshimasa HARUMOTO
  • Patent number: 11999788
    Abstract: A therapeutic or prophylactic agent for radiation damage associated with radiation exposure, comprising an eosinophil-removing agent as an active ingredient and the like are provided as a technique for efficiently treating or preventing radiation damage associated with radiation exposure. According to the therapeutic or prophylactic agent comprising an eosinophil-removing agent according to the present invention, by suppressing migration and/or infiltration into target tissue and/or proliferation in the tissue of eosinophils and/or inhibiting the activity or function of the eosinophils, pathological conditions such as inflammatory responses and fibrosis of tissue can be suppressed to effectively treat or prevent radiation damage. Moreover, effective radiation therapy can be performed by suppressing radiation damage.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: June 4, 2024
    Assignees: Kyowa Kirin Co., Ltd., The University of Tokyo
    Inventors: Kazuki Okada, Kiyotoshi Mori, Satoshi Uematsu, Naoki Takemura
  • Publication number: 20240156879
    Abstract: The present invention relates to a composition which contains an intestinal bacterium belonging to the genus Veillonella and having an inflammation reducing activity, or a substance derived from the intestinal bacterium and having an inflammation reducing activity and which has at least one activity selected from an anti-inflammatory activity, an immunoregulation activity, an epithelial barrier restoring activity, an IL-10-inducing activity, and an IL-22-inducing activity, and to an ameliorating agent for an inflammatory disease, an autoimmune disease, or an infectious disease containing the intestinal bacterium and the substance derived from the intestinal bacterium and having an inflammation reducing activity.
    Type: Application
    Filed: March 8, 2022
    Publication date: May 16, 2024
    Applicants: JUNTENDO EDUCATIONAL FOUNDATION, Kyowa Kirin Co., Ltd., KYOWA HAKKO BIO CO., LTD.
    Inventors: Dai ISHIKAWA, Satoshi KOIZUMI, Makoto YAMASHITA, Fuhito YAMAZAKI, Nakayuki HONMA, Itaru URAKAWA, Susumu IWAMOTO
  • Publication number: 20240148799
    Abstract: The present invention relates to a composition which contains an intestinal bacterium belonging to Bacteroidetes and having an inflammation reducing activity, or a substance derived from the intestinal bacterium and having an inflammation reducing activity and which has at least one activity selected from an anti-inflammatory activity, an immunoregulation activity, an epithelial barrier restoring activity, an IL-10-inducing activity, and an IL-22-inducing activity, and to an ameliorating agent for an inflammatory disease, an autoimmune disease, or an infectious disease containing the intestinal bacterium and the substance derived from the intestinal bacterium and having an inflammation reducing activity.
    Type: Application
    Filed: March 8, 2022
    Publication date: May 9, 2024
    Applicants: JUNTENDO EDUCATIONAL FOUNDATION, Kyowa Kirin Co., Ltd., KYOWA HAKKO BIO CO., LTD.
    Inventors: Dai ISHIKAWA, Satoshi KOIZUMI, Makoto YAMASHITA, Fuhito YAMAZAKI, Mikiro HAYASHI, Nakayuki HONMA, Itaru URAKAWA, Susumu IWAMOTO
  • Patent number: 11970531
    Abstract: An object of the present invention is to provide an anti-BMP10 antibody, and a therapeutic agent for hypertension and a hypertensive disease, containing the antibody as an active ingredient. The present invention relates to an anti-BMP10 monoclonal antibody or an antibody fragment thereof that binds to human BMP10 (bone morphogenetic protein 10). Further, the present invention relates to a therapeutic agent for hypertension and a hypertensive disease containing an antagonist for at least one of BMP10 and a BMP9/BMP10 heterodimer, a diagnostic agent or a pharmaceutical composition for a disease associated with human BMP10, an immunological detection method or a measurement method for human BMP10 using the antagonist, and use of the antagonist for producing a pharmaceutical composition for treating hypertension and a hypertensive disease.
    Type: Grant
    Filed: September 27, 2022
    Date of Patent: April 30, 2024
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Hiroyuki Ariyama, Shinya Ogawa, Tetsuya Kitayama, Takenao Yamada
  • Patent number: 11965035
    Abstract: The invention relates to an antibody which binds to chondroitin sulfate proteoglycan 5 (CSPG5) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: April 23, 2024
    Assignees: KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITY
    Inventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Yuji Ito
  • Publication number: 20240124577
    Abstract: The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.
    Type: Application
    Filed: August 1, 2023
    Publication date: April 18, 2024
    Applicants: Kyowa Kirin Co., Ltd., KAGOSHIMA UNIVERSITY
    Inventors: Nobuaki Takahashi, Ryosuke NAKANO, Sayaka MAEDA, Yuji ITO
  • Patent number: 11951103
    Abstract: The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: April 9, 2024
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Hiroki Haniuda, Sachiko Enokizono, Tomoyuki Nakazato, Takuya Tokuda, Norie Fujiki